Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now.
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results